Exhibit 99.1

GPN NETWORK ANNOUNCES CHANGE OF CORPORATE NAME AND TICKER SYMBOL: IR BIOSCIENCES
HOLDINGS, INC.


Scottsdale,  AZ.,  August 27, 2003 - - GPN Network,  Inc. (OTC  Bulletin  Board:
GPNW)  announced  today that  effective  August 28, 2003, the Company's new name
will be "IR  BioSciences  Holdings,  Inc." The Company is the parent  company of
ImmuneRegen BioSciences, Inc., a research and development biotechnology company,
and its common stock will begin trading under the new ticker symbol: IRBH. A new
Cusip number has been assigned to the Company's common stock.

The Company said it will issue new stock certificates  bearing the Company's new
name in the ordinary  course of trading and  re-issuance  and does not intend to
solicit the exchange of outstanding  stock  certificates.  Stockholders  holding
their GPN  Network  shares in street  name will see the  Company's  name  change
reflected  in  future  statements.   Accordingly,   no  action  is  required  by
stockholders  with respect to their stock  certificates or shares held in street
name.

About IR BioSciences Holdings, Inc.

The Company is the parent  company of its wholly owned  subsidiary,  ImmuneRegen
BioSciences, Inc. ImmuneRegen is a biotechnology company engaged in the research
and  development of  applications  utilizing  modified  Substance P, a naturally
occurring immunomodulator. Derived from homeostatic substance P, ImmuneRegen has
named its proprietary compound "Homspera." ImmuneRegen's initial focus is on the
continuing development of Homspera for various applications for use in improving
pulmonary   function  and  stimulating   the  human  immune  system.   For  more
information, please visit ImmuneRegen's website at www.immuneregen.com .

About Homspera

ImmuneRegen's  patents  and  continued  substance P research  are  derived  from
discoveries  made during  research  funded by the Air Force Office of Scientific
Research in the early 1990s. During this research, Dr. Witten and his associates
observed  that the  exposure of animals to jet fuels  resulted  in  pathological
changes in the lung and immune  systems of those  exposed.  It was also observed
that such  exposure  resulted in  depletion of substance P from the lungs of the
animals. These studies further showed that the administration of substance P may
help prevent and reverse the effects of jet fuel exposure in the lungs,  as well
as protect and regenerate the immune  system.  The immune  findings led to early
research on the  treatment  of exposure to acute  radiation  and on the possible
reversal of lung damage caused by Acute Respiratory Distress Syndrome (ARDS) and
cigarette smoke.

Statements  about the Company's future  expectations,  including future revenues
and  earnings,  and all  other  statements  in this  press  release  other  than
historical facts, are "forward-looking statements" within the meaning of Section
27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of
1934, and as that term is defined in the Private  Securities  Litigation  Reform
Act of 1995. The Company intends that such forward-looking statements be subject
to the safe harbors created  thereby.  The Company's actual results could differ
materially from expected  results as a result of a number of factors,  including
the  uncertainties  inherent in  research  collaborations,  clinical  trials and
product development  programs,  the evaluation of potential  opportunities,  the
level  of  available   capital  and  corporate   expenditures,   capital  market
conditions, and others set forth in the Company's periodic report on Form 8-K as
filed with the Securities and Exchange Commission on July 7, 2003.